Shin Poong Pharm.Co.Ltd. (KO:019170) — Market Cap & Net Worth
Market Cap & Net Worth: Shin Poong Pharm.Co.Ltd. (019170)
Shin Poong Pharm.Co.Ltd. (KO:019170) has a market capitalization of $390.33 Million (₩575.98 Billion) as of May 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #13799 globally and #461 in its home market, demonstrating a 1.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shin Poong Pharm.Co.Ltd.'s stock price ₩11690.00 by its total outstanding shares 49271029 (49.27 Million). Analyse cash flow conversion of Shin Poong Pharm.Co.Ltd. to see how efficiently the company converts income to cash.
Shin Poong Pharm.Co.Ltd. Market Cap History: 2015 to 2026
Shin Poong Pharm.Co.Ltd.'s market capitalization history from 2015 to 2026. Data shows growth from $145.00 Million to $390.33 Million (10.22% CAGR).
Shin Poong Pharm.Co.Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shin Poong Pharm.Co.Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Shin Poong Pharm.Co.Ltd.'s market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $145.00 Million | $195.95 Billion | $1.48 Billion | 0.00x | 0.10x |
| 2016 | $197.88 Million | $194.15 Billion | -$18.59 Billion | 0.00x | N/A |
| 2017 | $255.75 Million | $185.00 Billion | $904.89 Million | 0.00x | 0.28x |
| 2018 | $213.18 Million | $187.39 Billion | $2.80 Billion | 0.00x | 0.08x |
| 2019 | $240.78 Million | $189.72 Billion | $5.32 Billion | 0.00x | 0.05x |
| 2020 | $4.13 Billion | $197.75 Billion | $5.00 Billion | 0.02x | 0.83x |
| 2021 | $1.07 Billion | $189.24 Billion | -$11.58 Billion | 0.01x | N/A |
| 2022 | $706.20 Million | $209.29 Billion | -$35.38 Billion | 0.00x | N/A |
| 2023 | $451.44 Million | $200.23 Billion | -$57.33 Billion | 0.00x | N/A |
| 2024 | $344.25 Million | $221.09 Billion | -$15.39 Billion | 0.00x | N/A |
Competitor Companies of 019170 by Market Capitalization
Companies near Shin Poong Pharm.Co.Ltd. in the global market cap rankings as of May 4, 2026.
Key companies related to Shin Poong Pharm.Co.Ltd. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Shin Poong Pharm.Co.Ltd. Historical Marketcap From 2015 to 2026
Between 2015 and today, Shin Poong Pharm.Co.Ltd.'s market cap moved from $145.00 Million to $ 390.33 Million, with a yearly change of 10.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩390.33 Million | -16.74% |
| 2025 | ₩468.80 Million | +36.18% |
| 2024 | ₩344.25 Million | -23.74% |
| 2023 | ₩451.44 Million | -36.08% |
| 2022 | ₩706.20 Million | -33.80% |
| 2021 | ₩1.07 Billion | -74.15% |
| 2020 | ₩4.13 Billion | +1614.23% |
| 2019 | ₩240.78 Million | +12.95% |
| 2018 | ₩213.18 Million | -16.64% |
| 2017 | ₩255.75 Million | +29.24% |
| 2016 | ₩197.88 Million | +36.47% |
| 2015 | ₩145.00 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Shin Poong Pharm.Co.Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $390.33 Million USD |
| MoneyControl | $390.33 Million USD |
| MarketWatch | $390.33 Million USD |
| marketcap.company | $390.33 Million USD |
| Reuters | $390.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shin Poong Pharm.Co.Ltd.
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more